How Far Have We Developed Antibody–Drug Conjugate for the Treatment of Cancer?

Cancer, also known as malignant tumour or neoplasm, is a leading cause of death worldwide. One distinct feature from normal cells is that cancerous cells often overexpress protein on the cell membrane—for instance, the overexpression of human epidermal growth factor receptor 2. The expression of a s...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Drugs and Drug Candidates
المؤلفون الرئيسيون:	Yu Jun Lim, Pei Sze Clarissa Lau, Shi Xuan Low, Shong Li Ng, Min Yee Ong, Huey Ming Pang, Zheng Yang Lee, Hui Yin Yow, Sharina Binti Hamzah, Renukha Sellappans, Jhi Biau Foo
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	MDPI AG 2023-05-01
الموضوعات:	cancer antibody–drug conjugate clinical trials linker cytotoxin
الوصول للمادة أونلاين:	https://www.mdpi.com/2813-2998/2/2/20